Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.
Standard
Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. / Bohuslavizki, K H; Brenner, Winfried; Braunsdorf, W E; Behnke, A; Tinnemeyer, S; Hugo, H H; Jahn, N; Wolf, H; Sippel, C; Clausen, M; Mehdorn, H M; Henze, E.
in: NUCL MED COMMUN, Jahrgang 17, Nr. 4, 4, 1996, S. 302-310.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.
AU - Bohuslavizki, K H
AU - Brenner, Winfried
AU - Braunsdorf, W E
AU - Behnke, A
AU - Tinnemeyer, S
AU - Hugo, H H
AU - Jahn, N
AU - Wolf, H
AU - Sippel, C
AU - Clausen, M
AU - Mehdorn, H M
AU - Henze, E
PY - 1996
Y1 - 1996
N2 - The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in patients with meningioma proven or suspected on magnetic resonance imaging (MRI). Prior to surgery, 47 patients were investigated up to 24 h following the injection of 200 MBq 111In-octreotide. Tracer uptake was compared with the histological presence of meningioma. Histology revealed 43 meningiomas, 3 neurinomas and 1 ependymoma. A true-positive SRS result was obtained in 36 patients, in 13 of whom a tumour volume of <10 ml was noted. A false-negative SRS result was obtained in seven patients, all of whom had a tumour volume of <10 ml. Whereas MRI alone was decisive in 38 of 47 patients, it could only provide a differential diagnosis in the remaining 9 patients. A positive SRS result confirmed meningioma in five of these patients, and a negative SRS result excluded meningioma in the other four. Therefore, cases of SRS-negative meningioma do exist. Nevertheless, significant clinical benefit can be obtained from functional imaging with 111In-octreotide in patients with an inconclusive MRI result, as large meningiomas can be excluded by scintigraphy alone, whereas meningiomas of any size may be confirmed in combination with specific MRI results.
AB - The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in patients with meningioma proven or suspected on magnetic resonance imaging (MRI). Prior to surgery, 47 patients were investigated up to 24 h following the injection of 200 MBq 111In-octreotide. Tracer uptake was compared with the histological presence of meningioma. Histology revealed 43 meningiomas, 3 neurinomas and 1 ependymoma. A true-positive SRS result was obtained in 36 patients, in 13 of whom a tumour volume of <10 ml was noted. A false-negative SRS result was obtained in seven patients, all of whom had a tumour volume of <10 ml. Whereas MRI alone was decisive in 38 of 47 patients, it could only provide a differential diagnosis in the remaining 9 patients. A positive SRS result confirmed meningioma in five of these patients, and a negative SRS result excluded meningioma in the other four. Therefore, cases of SRS-negative meningioma do exist. Nevertheless, significant clinical benefit can be obtained from functional imaging with 111In-octreotide in patients with an inconclusive MRI result, as large meningiomas can be excluded by scintigraphy alone, whereas meningiomas of any size may be confirmed in combination with specific MRI results.
M3 - SCORING: Zeitschriftenaufsatz
VL - 17
SP - 302
EP - 310
JO - NUCL MED COMMUN
JF - NUCL MED COMMUN
SN - 0143-3636
IS - 4
M1 - 4
ER -
